



DATE: June 25, 2014

SUBJECT: Long Term Care Provider Bulletin No. 2012-11-29
National Partnership to Improve Dementia Care and Reduce Antipsychotic
Drug Use in Nursing Homes

TO: Nursing Home Administrators

FROM: Susan Y. Williamson, Director
Division of Nursing Care Facilities
Bureau of Facility Licensure and Certification
(717) 787-1816

On May 30, 2012, CMS launched a new initiative aimed at improving care of residents with dementia and safeguarding nursing home residents from unnecessary antipsychotic drug use. The Division of Nursing Care Facilities (DNCF) supports CMS in this initiative and has devised the following plan in an effort to decrease the antipsychotic drug use in Pennsylvania's nursing homes.

DNCF recognizes that there are high rates of antipsychotic drug use in nursing homes. We also realize that facilities are faced with many challenges on a daily basis. It is our plan to assist facilities with this challenge through a process of recognition, education and networking.

Recognition:

1. Facilities submit CMS 672 forms (Census and Condition) during each recertification survey, at least every 15 months. Contained on the CMS 672 form is the resident census (F78) at the time of the survey and the number of residents receiving antipsychotic medications (F134).
2. DNCF will analyze the data that the facility submits on the CMS 672 form. The information will be compared to the previous recertification survey data submitted on the CMS 672 form.
3. If the percentage (%) of antipsychotic use is greater than the previous recertification survey, the facility will receive a letter from DNCF indicating that and encouraging the facility to review the residents and care plans. Additionally, they will be encouraged to access the educational information on the DOH

Pennsylvania Department of Health
Division of Nursing Care Facilities
Implementation: November 29, 2012
Bulletin Last Reviewed: November 29, 2012
Reviewed: May 28, 2013
Reviewed: June 25, 2014

website, as well as, contacting DNCF to provide educational assistance and networking opportunities.

4. If the % of antipsychotic use remains unchanged or is less than the previous recertification survey, the facility will receive a letter from DNCF providing positive feedback and requesting that the facility share their best practices with others by submitting them to DNCF for posting on our website.

Education & Networking:

1. The entrance conference checklist will be updated to include discussion of facility antipsychotic drug use.
2. The survey team will review the antipsychotic drug use that the facility reported on the previous recertification survey on the 672 &/or the QM reports, and share that information with the administrator upon entrance for the full health survey.
3. The survey team will inform the administrator of available resources regarding education & support for improving dementia care (the website- <http://www.portal.state.pa.us/portal/server.pt?open=514&objID=1328934&mode=2>). Additionally, the survey team will answer any questions.
4. A letter will be forwarded to all stakeholders identified by CMS indicating DNCF's support of the initiative and requesting best practice information they would like to share.
5. A letter will be forwarded to all Hospitals requesting their cooperation with the initiative.
6. A link has been set up on the DOH website to store best practice and education information (see #3).
7. Educational information from reputable sources will be made available on the web for free.
8. Stakeholders and providers will submit their best practices or other general educational information to the DNCF central office for review.
9. All DNCF staff, either central office or field office, will entertain questions from providers regarding the initiative and will connect the provider to educational resources.